Top fibrosis Articles in Internal Medicine

Vitamin D supplementation for cystic fibrosis
Cochrane Reviews, 10/28/2009

Ferguson JH et al. – Cystic fibrosis with pancreatic insufficiency can cause vitamins, such as vitamin D, to be inadequately absorbed leading to vitamin deficiencies. Lack of vitamin D (vitamin D deficiency) can cause specific problems such as ... can also be associated with poorer general and respiratory health. Thus, people with cystic fibrosis are usually given regular vitamin D preparations from a very young age. However, excess vitamin D can also cause respiratory problems and problems with high calcium levels. The review contains three ... cystic fibrosis is beneficial or not. The authors are unable to draw any conclusions regarding the routine administration of Vitamin D supplements and recommend that until further evidence is available, local guidelines are followed regarding this practice. [more...]

Pulmonary nocardiosis in cystic fibrosis
Journal of Cystic Fibrosis, 10/07/2009

Thorn ST et al. – Oral antibiotic therapy of cystic fibrosis patients colonized with Nocardia does not appear to affect clinical outcome. This suggests that deferring therapy may be an acceptable alternative and justifies conducting a future placebo ... this study model may be useful in analyzing the effect of therapy on other rare and difficult organisms, such as fungi and mycobacteria in the cystic fibrosis population. [more...]

Antifibrotic effects of green tea on in vitro and in vivo models of liver fibrosis
World Journal of Gastroenterology, 11/12/2009

Kim HK et al. – The study demonstrates that green tea administration can effectively improve liver fibrosis caused by DMN, and may be used as a therapeutic option and preventive measure against hepatic fibrosis. [more...]

Genetic Risk Factor for Liver Disease for Patients With Cystic Fibrosis
Gastroenterology, 10/27/2009

Lang LH – A genetic analysis indicates that a certain gene variation in patients with cystic fibrosis may significantly increase their risk of developing severe liver disease, according to a study in the September 9 issue of JAMA. [more...]

Targeted Injury of Type II Alveolar Epithelial Cells Induces Pulmonary Fibrosis
American Journal of Respiratory and Critical Care Medicine, 10/28/2009

Sisson TH et al. – The development of lung fibrosis in the setting of type II cell injury in the model provides evidence for a causal link between the epithelial defects seen in IPF and the corresponding areas of scarring. [more...]

Inspire Announces Presentation at the North American Cystic Fibrosis Conference and Provides Enrollment Update for Phase 3 Cystic Fibrosis Trial
Inspire, 10/16/2009

Inspire Pharmaceuticals, Inc. announced Inspire scientists and collaborators will present data from the denufosol tetrasodium cystic fibrosis (CF) program in a poster presentation at ... Cystic Fibrosis Conference (NACFC) October 15 – 17, 2009 in Minneapolis, MN. [more...]

Diabetes as a Determinant of Mortality in Cystic Fibrosis
Diabetes Care, 11/20/2009

Chamnan P et al. – Individuals with cystic fibrosis (CF) die earlier with diabetes, which, if delayed or better treated, might reasonably extend survival, and merits testing. [more...]

Chances and limitations of non-invasive tests in the assessment of liver fibrosis in liver transplant patients
Clinical Transplantation, 11/20/2009

Kamphues C et al. – The transient elastography is a reliable test for exclusion of liver cirrhosis in HCV transplant and significant liver fibrosis in alcoholic transplant patients. For the diagnosis of significant liver fibrosis in HCV ... results but cannot replace liver biopsy. Both serum markers AST–to–platelet ratio index and FIB–4 are not feasible to assess liver fibrosis in liver transplant patients. [more...]

Gadolinium-Associated Nephrogenic Systemic Fibrosis
American Family Physician, 10/01/2009

Schlaudecker JD et al. – Nephrogenic systemic fibrosis is a progressive, potentially fatal multiorgan system fibrosing disease related to exposure of patients with renal failure to the gadolinium–based contrast agents used in magnetic ... relationship between nephrogenic systemic fibrosis and gadolinium–based contrast agents, the U.S. Food and Drug Administration currently warns against using gadolinium–based contrast agents in patients with a glomerular filtration rate less than 30 mL per minute per 1.73 m2, or any acute ... hepatorenal syndrome or perioperative liver transplantation. There have been reports of nephrogenic systemic fibrosis developing in patients not exposed to gadolinium–based contrast agents, but most patients have the triad of gadolinium exposure through contrast–enhanced magnetic ... sepsis. [more...]

Clinical Predictors of Hepatic Fibrosis in Chronic Advanced Heart Failure
Circulation: Heart Failure, 10/19/2009

Gelow JW et al. – Hepatic fibrosis is common in advanced HF patients. Renal dysfunction, significant TR and abnormal LFTs are associated with hepatic fibrosis, but the predictive value of other clinical features is [more...]